Macquarie University researchers have discovered new information about how oral cancer cells may block the body's immune response. This could lead to...
Vous n'êtes pas connecté
Scientists at the University of Southampton have uncovered how the immune system's natural killer cells can target a protein known as XPO1, which promotes cancer. By hijacking this protein, they may activate more killer cells to destroy cancer cells. This discovery could lead to new, less invasive cancer treatments, showing promise for personalized immunotherapy.
Macquarie University researchers have discovered new information about how oral cancer cells may block the body's immune response. This could lead to...
Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to...
Researchers have made a significant breakthrough in understanding how oral cancer cells evade the body's immune system, leading to potential new...
Researchers at Macquarie University have made a significant breakthrough in understanding how medlinkoral cancer/medlink cells evade the body's...
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins...
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins...
What is circulating cell-free DNA, and how can it change healthcare? Discover how cfDNA offers non-invasive insights for cancer, prenatal care, and...
Immune checkpoint blockade (ICB) is one of the primary methods of tumour immunotherapy. It involves reactivating the immune system, which cancer has...
Cancer vaccine shows promise A new cancer vaccine, mRNA-4359, developed by Moderna, could revolutionise cancer treatment. This vaccine is designed...
Learn how sensory neurons and immune cells interact to trigger allergic reactions and explore new therapeutic pathways for preventing allergies.